NKTR (Nektar Therapeutics) Debt-to-Asset : 0.34 (As of Dec. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Debt-to-Asset?

Nektar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $19.87 Mil. Nektar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $82.70 Mil. Nektar Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $303.85 Mil. Nektar Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.34.

Nektar Therapeutics Debt-to-Asset Historical Data

The historical data trend for Nektar Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Debt-to-Asset Chart

Nektar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.13

0.19

0.30

0.34

Nektar Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.30	0.29	0.33	0.35	0.34

Competitive Comparison of Nektar Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Nektar Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Nektar Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nektar Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(19.868	+	82.696)	/	303.85
	=	0.34

Nektar Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(19.868	+	82.696)	/	303.85
	=	0.34

Nektar Therapeutics (NAS:NKTR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nektar Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NKTR:Mexico 0UNL:UK ITH:Germany ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Executives

Howard W Robin	director, officer: President & CEO
Jonathan Zalevsky	officer: Chief R&D Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson	officer: SVP & General Counsel	1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess	director, officer: Executive Chairman
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner	officer: Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen	officer: VP & Chief Accounting Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie	officer: SVP, COO & CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott	officer: SVP & Chief Commercial Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer	director	6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau	director	15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein	officer: Chief Scientific Officer	129 ELSIE STREET, SAN FRANCISCO CA 94110